Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RENESE-R vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Edema due to congestive heart failure,Mild to moderate hypertension
Hypertension
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Metabolized by liver (CYP450) to active metabolite; excreted in feces (65%) and urine (35%).
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
80-90% bound to plasma proteins, primarily albumin
Approximately 70-80% bound to plasma proteins, primarily albumin.
0.2-0.3 L/kg; indicates distribution mainly in extracellular fluid
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 70-80%
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Initiate at 2.5 mg orally once daily; use caution due to increased sensitivity to electrolyte disturbances and hypotension.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
No FDA boxed warning.
None.
May cause hypokalemia and hypomagnesemia,Can precipitate hyperuricemia and gout,May increase serum calcium,Use with caution in diabetes (may increase blood glucose),Photosensitivity reactions reported,Sulfonamide allergy: possible cross-reactivity
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Anuria,Hypersensitivity to sulfonamides or thiazides,Severe renal impairment (creatinine clearance <30 m L/min),Hepatic coma or pre-coma
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid excessive salt intake as it can reduce the antihypertensive effect. Limit alcohol consumption, which may enhance orthostatic hypotension. High-potassium foods (e.g., bananas, oranges, spinach) are generally safe but monitor potassium levels as thiazides can cause hypokalemia; supplement potassium if indicated. Grapefruit juice has no known interaction with this combination.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults. Because thiazides cross the placental barrier and appear in cord blood, use during the third trimester may cause electrolyte disturbances, hypoglycemia, and other effects. The drug should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Thiazides are excreted in human milk in small amounts. There is no published M/P ratio for polythiazide specifically; however, based on thiazide class, the M/P ratio is approximately 0.1-0.5. Breastfeeding is generally discouraged due to potential for adverse effects in the infant, including electrolyte imbalance and thrombocytopenia. Alternative agents are preferred, especially in high-dose therapy or when monitoring is not feasible.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Pregnancy may alter pharmacokinetics of thiazides due to increased plasma volume and renal blood flow. Dose adjustments are not well established; however, polythiazide should be used at the lowest effective dose to avoid excessive diuresis and electrolyte imbalances. If used, monitor maternal electrolytes and renal function closely. The dose may need to be reduced if signs of hypovolemia or electrolyte abnormalities develop. Postpartum, consider dose readjustment as plasma volume normalizes.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Renese-R is a fixed-dose combination of polythiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid antihypertensive. Watch for hypokalemia, especially in patients on digoxin. Reserpine can cause significant bradycardia and depression; avoid in patients with history of depression. Discontinue at least 2 weeks before electroconvulsive therapy. Monitor for orthostatic hypotension, especially when used with other antihypertensives.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Avoid alcohol and standing up quickly from lying or sitting positions to prevent dizziness.,Report symptoms of depression, severe drowsiness, or slow heartbeat to your doctor immediately.,You may need to have regular blood tests to monitor potassium levels and kidney function.,This medication can cause increased sensitivity to sunlight; use sunscreen and protective clothing.,Do not stop taking this drug abruptly without consulting your doctor.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RENESE-R vs ALDOCLOR-150, answered by our medical review team.
RENESE-R is a Antihypertensive Combination that works by Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RENESE-R and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RENESE-R is: Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RENESE-R and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RENESE-R is classified as Category C. Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaund. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.